{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T02:24:28Z","timestamp":1779935068781,"version":"3.53.1"},"reference-count":57,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.3892\/etm.2017.5003","type":"journal-article","created":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T11:39:38Z","timestamp":1503401978000},"page":"3491-3500","source":"Crossref","is-referenced-by-count":24,"title":["Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials"],"prefix":"10.3892","volume":"14","author":[{"given":"Zhigao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2017,8,22]]},"reference":[{"key":"key20180108135609_b1-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados","year":"2011","journal-title":"Lancet"},{"key":"key20180108135609_b2-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.39008","article-title":"Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis","volume":"67","author":"Mease","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20180108135609_b3-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: Recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20180108135609_b4-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"key20180108135609_b5-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/art.21330","article-title":"Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy","volume":"53","author":"Davis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key20180108135609_b6-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jbspin.2014.01.003","article-title":"Should non-steroidal anti-inflammatory drugs be used continuously in ankylosing spondylitis?","volume":"81","author":"Guellec","year":"2014","journal-title":"Joint Bone Spine"},{"key":"key20180108135609_b7-etm-0-0-5003","first-page":"1017","article-title":"Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: A systematic review of the literature","volume":"27","author":"Visser","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"key20180108135609_b8-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/14740338.4.4.723","article-title":"Methotrexate pulmonary toxicity","volume":"4","author":"Lateef","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"key20180108135609_b9-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: A comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"key20180108135609_b10-etm-0-0-5003","first-page":"CD005468","article-title":"TNF-alpha inhibitors for ankylosing spondylitis","volume":"18","author":"Maxwell","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"key20180108135609_b11-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.berh.2014.10.001","article-title":"Adverse effects of TNF inhibitors in SpA: Are they different from RA?","volume":"28","author":"Sampaio-Barros","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key20180108135609_b12-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3899\/jrheum.160594","article-title":"Physical function and spinal mobility remain stable despite radiographic spinal progression in patients with ankylosing spondylitis treated with TNF-\u03b1 inhibitors for Up to 10 Years","volume":"43","author":"Poddubnyy","year":"2016","journal-title":"J Rheumatol"},{"key":"key20180108135609_b13-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcms.2010.11.001","article-title":"Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias","volume":"39","author":"Knobloch","year":"2011","journal-title":"J Craniomaxillofac Surg"},{"key":"key20180108135609_b14-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The assessment of SpondyloArthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20180108135609_b15-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ard.2006.056747","article-title":"Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis","volume":"65","author":"van der Heijde","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key20180108135609_b16-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"key20180108135609_b17-etm-0-0-5003","first-page":"S38","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","volume":"5","author":"Higgins","year":"2011","journal-title":"Naunyn-Schmiedebergs Archiv f\u00fcr experimentelle Pathologie und Pharmakologie"},{"key":"key20180108135609_b18-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: A comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"Bradburn","year":"2007","journal-title":"Stat Med"},{"key":"key20180108135609_b19-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"406","DOI":"10.5301\/hipint.5000033","article-title":"The efficacy and safety of infliximab used in patients with ankylosing spondylitis after unilateral total hip arthroplasty","volume":"23","author":"Wang","year":"2013","journal-title":"Hip Int"},{"key":"key20180108135609_b20-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: A multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key20180108135609_b21-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","article-title":"Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: A randomized, double-blind trial","volume":"63","author":"Braun","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key20180108135609_b22-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1136\/ard.2009.121533","article-title":"A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: The HEEL trial","volume":"69","author":"Dougados","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20180108135609_b23-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key20180108135609_b24-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"key20180108135609_b25-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Enbrel Ankylosing Spondylitis Study Group: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key20180108135609_b26-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key20180108135609_b27-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"key":"key20180108135609_b28-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: Results from the double-blind, placebo-controlled INFAST study, Part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20180108135609_b29-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard.2011.152223","article-title":"RESPOND investigators: Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: The RESPOND study","volume":"71","author":"Baranauskaite","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20180108135609_b30-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/ard.2004.022582","article-title":"Infliximab in combination with methotrexate in active ankylosing spondylitis: A clinical and imaging study","volume":"64","author":"Marzo-Ortega","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20180108135609_b31-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group: Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key20180108135609_b32-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key20180108135609_b33-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.511","article-title":"Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy","volume":"46","author":"Van Den Bosch","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key20180108135609_b34-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"key20180108135609_b35-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: Results of a randomised, controlled trial","volume":"73","author":"Huang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20180108135609_b36-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: Results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20180108135609_b37-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1136\/annrheumdis-2012-202245","article-title":"Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis","volume":"72","author":"Paramarta","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20180108135609_b38-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"R230","DOI":"10.1186\/ar4072","article-title":"Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): Significant short term improvement","volume":"14","author":"Horneff","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"key20180108135609_b39-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key20180108135609_b40-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key20180108135609_b41-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20180108135609_b42-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3109\/03009742.2015.1038300","article-title":"Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: A 48-week open randomized trial","volume":"44","author":"Mok","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"key20180108135609_b43-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/acr.22594","article-title":"Impact of certolizumab pegol on patient-reported outcomes in patients with axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"key20180108135609_b44-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20180108135609_b45-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20180108135609_b46-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.berh.2011.10.004","article-title":"Anti-TNF therapy","volume":"25","author":"Thalayasingam","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key20180108135609_b47-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coph.2010.01.005","article-title":"Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases","volume":"10","author":"Taylor","year":"2010","journal-title":"Curr Opin Pharmacol"},{"key":"key20180108135609_b48-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrrheum.2009.279","article-title":"Tumor necrosis factor blockade and the risk of viral infection","volume":"6","author":"Kim","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"key20180108135609_b49-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/art.23396","article-title":"The risk of infection associated with tumor necrosis factor alpha antagonists: Making sense of epidemiologic evidence","volume":"58","author":"Solomon","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20180108135609_b50-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1086\/587990","article-title":"Tumor necrosis factor-alpha at the intersection of mycobacterial immunity and pathogenesis: An important new address in medicine","volume":"46","author":"Iseman","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key20180108135609_b51-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Biobadaser Group: Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"Gomez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key20180108135609_b52-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/art.21688","article-title":"Anti-tumor necrosis factor alpha therapy and the risk of JC virus infection","volume":"54","author":"Roos","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key20180108135609_b53-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1136\/ard.2008.098822","article-title":"Serious infections in patients with ankylosing spondylitis with and without TNF blockers: A systematic review and meta-analysis of randomised placebo-controlled trials","volume":"69","author":"Fouque-Aubert","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20180108135609_b54-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/rheumatology\/keq368","article-title":"Registries in rheumatoid arthritis and autoimmune diseases: Data from the French registries","volume":"50","author":"Mariette","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"key20180108135609_b55-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"B S R B R Control Centre Consortium, Symmons DP; BSR Biologics Register: Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British society for rheumatology biologics register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20180108135609_b56-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1086\/505430","article-title":"Tumor-necrosis-factor blockers: Differential effects on mycobacterial immunity","volume":"194","author":"Saliu","year":"2006","journal-title":"J Infect Dis"},{"key":"key20180108135609_b57-etm-0-0-5003","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/art.23285","article-title":"Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade","volume":"58","author":"Wallis","year":"2008","journal-title":"Arthritis Rheum"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T00:25:01Z","timestamp":1515457501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/etm.2017.5003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,22]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,8,22]]},"published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.3892\/etm.2017.5003"],"URL":"https:\/\/doi.org\/10.3892\/etm.2017.5003","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,22]]}}}